Lyme borreliosis: reviewing potential vaccines, clinical aspects and health economics

References

• Steere AC, Malawista SE, Hardin JA, et al. Erythema chronicum migrans and Lyme arthritis: the enlarging clinical spectrum. Ann Intern Med 1977;86(6):685-98
   PubMed Web of Science ®Google Scholar
• Stanek G, Fingerle V, Hunfeld K, et al. Lyme borreliosis: clinical case definitions for diagnosis and management in Europe. Clin Microbiol Infect 2011;17(1):69-79
   PubMed Web of Science ®Google Scholar
• Stanek G, Wormser GP, Gray J, Strle F. Lyme borreliosis. Lancet 2012;379(9814):461-73
   PubMed Web of Science ®Google Scholar
• Stanek G, Reiter M. The expanding Lyme Borrelia complex-clinical significance of genomic species? Clin Microbiol Infect 2011;17(4):487-93
   PubMed Web of Science ®Google Scholar
• Diza E, Papa A, Vezyri E, et al. Borrelia valaisiana in cerebrospinal fluid. Emerging Infect Dis 2004;10(9):1692-3
   PubMed Web of Science ®Google Scholar
• de Carvalho IL, Fonseca J, Marques J, et al. Vasculitis-like syndrome associated with Borrelia lusitaniae infection. Clin Rheumatol 2008;27(12):1587-91
   PubMed Web of Science ®Google Scholar
• Rudenko N, Golovchenko M, Mokracek A, et al. Detection of Borrelia bissettii in cardiac valve tissue of a patient with endocarditis and aortic valve stenosis in the Czech Republic. J Clin Microbiol 2008;46(10):3540-3
   PubMed Web of Science ®Google Scholar
• Margos G, Vollmer SA, Cornet M, et al. A new Borrelia species defined by multilocus sequence analysis of housekeeping genes. Appl Environ Microbiol 2009;75(16):5410-16
   PubMed Web of Science ®Google Scholar
• Stanek G, Strle F. Lyme borreliosis. Lancet 2003;362(9396):1639-47
   PubMed Web of Science ®Google Scholar
• Stanek G, Strle F. Lyme disease-European perspective. Infect Dis Clin North Am 2008;22(2):327-39
   PubMed Web of Science ®Google Scholar
• European centre for disease prevention and control (ECDC). Meeting report Expert consultation on TBD with emphasis on Lyme borreliosis and tick-borne encephalitis. 2015. Available from: http://ecdc.europa.eu/en/publications/Publications/1102_MER_Tickborne_2010.pdf
   Google Scholar
• van Dam AP, Kuiper H, Vos K, et al. Different genospecies of Borrelia burgdorferi are associated with distinct clinical manifestations of Lyme borreliosis. Clin Infect Dis 1993;17(4):708-17
   PubMed Web of Science ®Google Scholar
• Balmelli T, Piffaretti J. Association between different clinical manifestations of Lyme disease and different species of Borrelia burgdorferi sensu lato. Res Microbiol 1995;146(4):329-40
   PubMed Web of Science ®Google Scholar
• Ruzic-Sabljic E, Maraspin V, Lotric-Furlan S, et al. Characterization of Borrelia burgdorferi sensu lato strains isolated from human material in Slovenia. Wien Klin Wochenschr 2002;114(13-14):544-50
   PubMed Web of Science ®Google Scholar
• Jenkins A, Kristiansen BE, Allum AG, et al. Borrelia burgdorferi sensu lato and Ehrlichia spp. in Ixodes ticks from southern Norway. J Clin Microbiol 2001;39(10):3666-71
   PubMed Web of Science ®Google Scholar
• Fraenkel CJ, Garpmo U, Berglund J. Determination of novel Borrelia genospecies in Swedish Ixodes ricinus ticks. J Clin Microbiol 2002;40(9):3308-12
   PubMed Web of Science ®Google Scholar
• Humair P, Rais O, Gern L. Transmission of borrelia afzelii from apodemus mice and clethrionomys voles to Ixodes ricinus ticks: differential transmission pattern and overwintering maintenance. Parasitology 1999;118(01):33-42
   PubMed Web of Science ®Google Scholar
• Alekseev AN, Dubinina HV, Van De Pol I, Schouls LM. Identification of Ehrlichia spp. and Borrelia burgdorferi in Ixodes ticks in the Baltic regions of Russia. J Clin Microbiol 2001;39(6):2237-42
   PubMed Web of Science ®Google Scholar
• Gray J. Review The ecology of ticks transmitting Lyme borreliosis. Exp Appl Acarol 1998;22(5):249-58
   Web of Science ®Google Scholar
• Lindgren E, Jaenson TG, WHO. Lyme borreliosis in Europe: influences of climate and climate change, epidemiology, ecology and adaptation measures. Report EUR/04/5046250. World Health Organization Regional Office for Europe, Copenhagen; 2006
   Google Scholar
• Centers for disease control and prevention (CDC). Notice to readers: final 2012 reports of nationally notifiable infectious diseases. MMWR Morb Mortal Wkly Rep 2013;62(33):669-82
   PubMed Web of Science ®Google Scholar
• Wormser GP, Dattwyler RJ, Shapiro ED, et al. The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2006;43(9):1089-134
   PubMed Web of Science ®Google Scholar
• European union concerted action on lyme borreliosis (EUCALB). 2015. Available from: www.eucalb.com/
   Google Scholar
• O’Connell S. Recommendations for diagnosis and treatment of Lyme borreliosis: guidelines and consensus papers from specialist societies and expert groups in Europe and North America. 2015. Available from: www.aldf.com/pdf/ECCMID_Poster_4.22.10.pdf
   Google Scholar
• Wressnigg N, Barrett PN, Pollabauer EM, et al. A Novel multivalent OspA vaccine against Lyme borreliosis is safe and immunogenic in an adult population previously infected with Borrelia burgdorferi sensu lato. Clin Vaccine Immunol 2014;21(11):1490-9
   PubMed Web of Science ®Google Scholar
• SteereAC LI. Lyme disease vaccines. In: Plotkin SA, Orenstein WA, Offit PA, editors. Vaccines. 6th edition. Elsevier; Philadelphia, PA: 2012. p. 1122-32
   Google Scholar
• Steere AC, Sikand VK, Meurice F, et al. Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant. N Engl J Med 1998;339(4):209-15
   PubMed Web of Science ®Google Scholar
• Sigal LH, Zahradnik JM, Lavin P, et al. A vaccine consisting of recombinant Borrelia burgdorferi outer-surface protein A to prevent Lyme disease. N Engl J Med 1998;339(4):216-22
   PubMed Web of Science ®Google Scholar
• Meltzer MI, Dennis DT, Orloski KA. The cost effectiveness of vaccinating against Lyme disease. Emerg Infect Dis 1999;5(3):321-8
   PubMed Web of Science ®Google Scholar
• Shadick NA, Liang MH, Phillips CB, et al. The cost-effectiveness of vaccination against Lyme disease. Arch Intern Med 2001;161(4):554-61
   PubMed Web of Science ®Google Scholar
• Hsia EC, Chung JB, Schwartz JS, Albert DA. Cost-effectiveness analysis of the Lyme disease vaccine. Arthritis Rheumatism 2002;46(6):1651-60
   PubMed Web of Science ®Google Scholar
• Poland GA. Vaccines against Lyme disease: What happened and what lessons can we learn? Clin Infect Dis 2011;52(Suppl 3):s253-8
   PubMed Web of Science ®Google Scholar
• Gross DM, Forsthuber T, Tary-Lehmann M, et al. Identification of LFA-1 as a candidate autoantigen in treatment-resistant Lyme arthritis. Science 1998;281(5377):703-6
   PubMed Web of Science ®Google Scholar
• Steere AC, Drouin EE, Glickstein LJ. Relationship between immunity to Borrelia burgdorferi outer-surface protein A (OspA) and Lyme arthritis. Clin Infect Dis 2011;52(Suppl 3):s259-65
   PubMed Web of Science ®Google Scholar
• Nardelli DT, Munson EL, Callister SM, Schell RF. Human Lyme disease vaccines: past and future concerns. Future Microbiol 2009;4(4):457-69
   PubMed Web of Science ®Google Scholar
• Comstedt P, Hanner M, Schüler W, et al. Design and Development of a Novel Vaccine for Protection against Lyme Borreliosis. PLoS One 2014;9(11):e113294
   PubMed Web of Science ®Google Scholar
• Wressnigg N, Pöllabauer E, Aichinger G, et al. Safety and immunogenicity of a novel multivalent OspA vaccine against Lyme borreliosis in healthy adults: a double-blind, randomised, dose-escalation phase 1/2 trial. Lancet Infect Dis 2013;13(8):680-9
   PubMed Web of Science ®Google Scholar
• Kuehn BM. CDC estimates 300 000 US cases of Lyme disease annually. JAMA 2013;310(11):1110-0
   PubMed Web of Science ®Google Scholar
• Centers for disease control and prevention (CDC). Lyme disease surveillance and available data. 2015. Available from: www.cdc.gov/lyme/stats/survfaq.html
   Google Scholar
• Bennet L, Halling A, Berglund J. Increased incidence of Lyme borreliosis in southern Sweden following mild winters and during warm, humid summers. Eur J Clin Microbiol Infect Dis 2006;25(7):426-32
   PubMed Web of Science ®Google Scholar
• Bacon RM, Kugeler KJ, Mead PS. Surveillance for Lyme disease-United States, 1992-2006. MMWR Surveill Summ 2008;57(10):1-9
   PubMedGoogle Scholar
• Fülöp B, Poggensee G. Epidemiological situation of Lyme borreliosis in Germany: Surveillance data from six Eastern German States, 2002 to 2006. Parasitol Res 2008;103(1):117-20
   Web of Science ®Google Scholar
• Hofhuis A, Van der Giessen J, Borgsteede F, et al. Lyme borreliosis in the Netherlands: strong increase in GP consultations and hospital admissions in past 10 years. Euro Surveill 2006;11(6):E060622
   Google Scholar
• Smith R, O’Connell S, Palmer S. Lyme disease surveillance in England and Wales, 1986 1998. Emerg. Infect Dis 2000;6(4):404-7
   PubMed Web of Science ®Google Scholar
• TäLleklint L, Jaenson TG. Increasing geographical distribution and density of Ixodes ricinus (Acari: Ixodidae) in central and northern Sweden. J Med Entomol 1998;35(4):521-6
   PubMed Web of Science ®Google Scholar
• Daniel M, Danielová V, Kříž B, et al. Shift of the tick Ixodes ricinus and tick-borne encephalitis to higher altitudes in central Europe. Eur J Clin Microbiol Infect Dis 2003;22(5):327-8
   PubMed Web of Science ®Google Scholar
• Lotric-Furlan S, Petrovec M, Avsic-Zupanc T, Strle F. Clinical distinction between human granulocytic ehrlichiosis and the initial phase of tick-borne encephalitis. J Infect 2000;40(1):55-8
   PubMed Web of Science ®Google Scholar
• Cimperman J, Maraspin V, Lotrič-Furlan S, et al. Concomitant infection with tick-borne encephalitis virus and Borrelia burgdorferi sensu lato in patients with acute meningitis or meningoencephalitis. Infection 1998;26(3):160-4
   PubMed Web of Science ®Google Scholar
• Krause PJ, Telford SR, Spielman A, et al. Concurrent Lyme disease and babesiosis: evidence for increased severity and duration of illness. JAMA 1996;275(21):1657-60
   PubMed Web of Science ®Google Scholar
• Rizzoli A, Hauffe HC, Carpi G, et al. Lyme borreliosis in Europe. Eurosurveillance 2011;16(27):19906
   Google Scholar
• CBO. Conceptrichtlijn Lymeziekte 2015 2012
   Google Scholar
• Nadelman RB, Wormser GP. Lyme borreliosis. Lancet 1998;352(9127):557-65
   PubMed Web of Science ®Google Scholar
• Ornstein K, Berglund J, Nilsson I, et al. Characterization of Lyme borreliosis isolates from patients with erythema migrans and neuroborreliosis in southern Sweden. J Clin Microbiol 2001;39(4):1294-8
   PubMed Web of Science ®Google Scholar
• Aguero-Rosenfeld ME. Lyme disease: laboratory issues. Infect Dis Clin North Am 2008;22(2):301-13
   PubMed Web of Science ®Google Scholar
• Strle F, Ruzic-Sabljic E, Cimperman J, et al. Comparison of findings for patients with Borrelia garinii and Borrelia afzelii isolated from cerebrospinal fluid. Clin Infect Dis 2006;43(6):704-10
   PubMed Web of Science ®Google Scholar
• Centers for disease control and prevention (CDC). Two-step Laboratory testing process. 2015. Available from: www.cdc.gov/lyme/diagnosistesting/LabTest/TwoStep/index.html
   Google Scholar
• Centers for disease control and prevention (CDC). Understanding the immunoblot test. 2015. Available from: www.cdc.gov/lyme/diagnosistesting/labtest/twostep/westernblot/index.html
   Google Scholar
• Steere AC, McHugh G, Damle N, Sikand VK. Prospective study of serologic tests for lyme disease. Clin Infect Dis 2008;47(2):188-95
   PubMed Web of Science ®Google Scholar
• Lebech A, Hansen K, Brandrup F, et al. Diagnostic value of PCR for detection of Borrelia burgdorferi DNA in clinical specimens from patients with erythema migrans and Lyme neuroborreliosis. Mol Diagn 2000;5(2):139-50
   PubMedGoogle Scholar
• Lazarus JJ, McCarter AL, Neifer-Sadhwani K, Wooten RM. ELISA-based measurement of antibody responses and PCR-based detection profiles can distinguish between active infection and early clearance of Borrelia burgdorferi. Clin Dev Immunol 2012;2012:138069
   PubMed Web of Science ®Google Scholar
• Wormser GP, Horowitz HW, Nowakowski J, et al. Positive Lyme disease serology in patients with clinical and laboratory evidence of human granulocytic ehrlichiosis. Am J Clin Pathol 1997;107(2):142-7
   PubMed Web of Science ®Google Scholar
• Strle F. Principles of the diagnosis and antibiotic treatment of Lyme borreliosis. Wien Klin Wochenschr 1999;111(22-23):911-15
   PubMed Web of Science ®Google Scholar
• Jaulhac B, Chary-Valckenaere I, Sibilia J, et al. Detection of Borrelia burgdorferi by DNA amplification in synovial tissue samples from patients with Lyme arthritis. Arthritis Rheumatism 1996;39(5):736-45
   PubMed Web of Science ®Google Scholar
• Priem S, Rittig MG, Kamradt T, et al. An optimized PCR leads to rapid and highly sensitive detection of Borrelia burgdorferi in patients with Lyme borreliosis. J Clin Microbiol 1997;35(3):685-90
   PubMed Web of Science ®Google Scholar
• Wilske B. Diagnosis of Lyme borreliosis in Europe. Vector-Borne Zoonotic Diseases 2003;3(4):215-27
   PubMed Web of Science ®Google Scholar
• Cerar T, Ogrinc K, Cimperman J, et al. Validation of cultivation and PCR methods for diagnosis of Lyme neuroborreliosis. J Clin Microbiol 2008;46(10):3375-9
   PubMed Web of Science ®Google Scholar
• Issakainen J, Gnehm HE, Lucchini GM, Zbinden R. Value of clinical symptoms, intrathecal specific antibody production and PCR in CSF in the diagnosis of childhood Lyme neuroborreliosis. Klin Padiatr 1996;208(3):106-9
   PubMed Web of Science ®Google Scholar
• Ornstein K, Berglund J, Bergström S, et al. Three major Lyme Borrelia genospecies (Borrelia burgdorferi sensu stricto, B. afzelii and B. garinii) identified by PCR in cerebrospinal fluid from patients with neuroborreliosis in Sweden. Scand J Infect Dis 2002;34(5):341-6
   PubMed Web of Science ®Google Scholar
• Aguero-Rosenfeld ME, Wang G, Schwartz I, Wormser GP. Diagnosis of lyme borreliosis. Clin Microbiol Rev 2005;18(3):484-509
   PubMed Web of Science ®Google Scholar
• Marques A, Brown MR, Fleisher TA. Natural killer cell counts are not different between patients with post-Lyme disease syndrome and controls. Clin Vaccine Immunol 2009;16(8):1249-50
   PubMed Web of Science ®Google Scholar
• Aguero-Rosenfeld ME, Wormser GP. Lyme disease: diagnostic issues and controversies. Exp Molec Diagnost 2015(0):1-4
   PubMed Web of Science ®Google Scholar
• Skogman BH, Glimaker K, Nordwall M, et al. Long-term clinical outcome after Lyme neuroborreliosis in childhood. Pediatrics 2012;130(2):262-9
   PubMed Web of Science ®Google Scholar
• Steere AC. Lyme Borreliosis. In: Kasper D, Fauci A, Hauser S, et al. editors. Harrison’s Principles of Internal Medicine. 19 edition. McGraw-Hill, New York; 2015. Available from: http://accessmedicine.mhmedical.com.proxy-ub.rug.nl/content.aspx?bookid=1130&Sectionid=79737623 [Last accessed 15 June 2015]
   Google Scholar
• Centers for disease control and prevention (CDC). Signs and Symptoms. 2015. Available from: www.cdc.gov/lyme/signs_symptoms/
   Google Scholar
• European centre for disease prevention and control (ECDC). Borreliosis. 2015. Available from: http://ecdc.europa.eu/en/healthtopics/emerging_and_vector-borne_diseases/tick_borne_diseases/lyme_disease/pages/index.aspx
   Google Scholar
• Maraspin V, Lotric-Furlan S, Cimperman J, et al. Erythema migrans in the immunocompromised host. Wien Klin Wochenschr 1999;111(22-23):923-32
   PubMed Web of Science ®Google Scholar
• Fürst B, Glatz M, Kerl H, Müllegger R. The impact of immunosuppression on erythema migrans. A retrospective study of clinical presentation, response to treatment and production of Borrelia antibodies in 33 patients. Clin Exp Dermatol 2006;31(4):509-14
   PubMed Web of Science ®Google Scholar
• Centers for disease control and prevention (CDC). Three sudden cardiac deaths associated with lyme carditis-United States, November 2012–July 2013. Available from: www.cdc.gov/mmwr/preview/mmwrhtml/mm6249a1.htm [Last accessed June 2015]
   Google Scholar
• Ackermann R, Rehse-Küpper B, Gollmer E, Schmidt R. Chronic neurologic manifestations of erythema migrans borreliosis. Ann N Y Acad Sci 1988;539(1):16-23
   PubMed Web of Science ®Google Scholar
• Kaiser R. Clinical courses of acute and chronic neuroborreliosis following treatment with ceftriaxone. Nervenarzt 2004;75(6):553-7
   PubMed Web of Science ®Google Scholar
• Müllegger RR, Glatz M. Skin manifestations of Lyme borreliosis. Am J Clin Dermatol 2008;9(6):355-68
   PubMed Web of Science ®Google Scholar
• Steere AC, Angelis SM. Therapy for Lyme arthritis: strategies for the treatment of antibiotic-refractory arthritis. Arthritis Rheumatism 2006;54(10):3079-86
   PubMed Web of Science ®Google Scholar
• Wormser GP, Nadelman RB, Schwartz I. The amber theory of Lyme arthritis: initial description and clinical implications. Clin Rheumatol 2012;31(6):989-94
   PubMed Web of Science ®Google Scholar
• Krupp LB, Hyman LG, Grimson R, et al. Study and treatment of post Lyme disease (STOP-LD): a randomized double masked clinical trial. Neurology 2003;60(12):1923-30
   PubMed Web of Science ®Google Scholar
• Kaplan RF, Trevino RP, Johnson GM, et al. Cognitive function in post-treatment Lyme disease: do additional antibiotics help? Neurology 2003;60(12):1916-22
   PubMed Web of Science ®Google Scholar
• Klempner MS, Hu LT, Evans J, et al. Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. N Engl J Med 2001;345(2):85-92
   PubMed Web of Science ®Google Scholar
• Seidel M, Domene AB, Vetter H. Differential diagnoses of suspected Lyme borreliosis or post-Lyme-disease syndrome. Eur J Clin Microbiol Infect Dis 2007;26(9):611-17
   PubMed Web of Science ®Google Scholar
• Fallon BA, Keilp JG, Corbera KM, et al. A randomized, placebo-controlled trial of repeated IV antibiotic therapy for Lyme encephalopathy. Neurology 2008;70(13):992-1003
   PubMed Web of Science ®Google Scholar
• Feder Jr HM, Johnson BJ, O’Connell S, et al. A critical appraisal of “chronic Lyme disease”. N Engl J Med 2007;357(14):1422-30
   PubMed Web of Science ®Google Scholar
• Wormser GP, Nowakowski J, Nadelman RB. Duration of treatment for Lyme borreliosis: time for a critical reappraisal. Wien Klin Wochenschr 2002;114(13-14):613-15
   PubMed Web of Science ®Google Scholar
• Klempner MS, Baker PJ, Shapiro ED, et al. Treatment trials for post-Lyme disease symptoms revisited. Am J Med 2013;126(8):665-9
   PubMed Web of Science ®Google Scholar
• Embers ME, Barthold SW, Borda JT, et al. Persistence of Borrelia burgdorferi in rhesus macaques following antibiotic treatment of disseminated infection. PLoS One 2012;7(1):e29914
   PubMed Web of Science ®Google Scholar
• Wormser GP, Schwartz I. Antibiotic treatment of animals infected with Borrelia burgdorferi. Clin Microbiol Rev 2009;22(3):387-95
   PubMed Web of Science ®Google Scholar
• Nadelman RB, Hanincová K, Mukherjee P, et al. Differentiation of reinfection from relapse in recurrent Lyme disease. N Engl J Med 2012;367(20):1883-90
   PubMed Web of Science ®Google Scholar
• Krause PJ, Foley DT, Burke GS, et al. Reinfection and relapse in early Lyme disease. Am J Trop Med Hyg 2006;75(6):1090-4
   PubMed Web of Science ®Google Scholar
• Nadelman RB, Wormser GP. Reinfection in patients with Lyme disease. Clin Infect Dis 2007;45(8):1032-8
   PubMed Web of Science ®Google Scholar
• Hanson MS, Edelman R. Progress and controversy surrounding vaccines against Lyme disease. Expert Rev Vaccines 2003;2(5):683-703
   Google Scholar
• Schuijt TJ, Hovius JW, van der Poll T, et al. Lyme borreliosis vaccination: the facts, the challenge, the future. Trends Parasitol 2011;27(1):40-7
   PubMed Web of Science ®Google Scholar
• Barbour AG, Tessier SL, Todd WJ. Lyme disease spirochetes and ixodid tick spirochetes share a common surface antigenic determinant defined by a monoclonal antibody. Infect Immun 1983;41(2):795-804
   PubMed Web of Science ®Google Scholar
• Bergström S, Bundoc V, Barbour A. Molecular analysis of linear plasmid-encoded major surface proteins, OspA and OspB, of the Lyme disease spirochaete Borrelia burgdorferi. Mol Microbiol 1989;3(4):479-86
   PubMed Web of Science ®Google Scholar
• Fuchs R, Jauris S, Lottspeich F, et al. Molecular analysis and expression of a Borrelia burgdorferi gene encoding a 22kDa protein (pC) in Escherichia coli. Mol Microbiol 1992;6(4):503-9
   PubMed Web of Science ®Google Scholar
• Earnhart CG, Rhodes DV, Marconi RT. Disulfide-mediated oligomer formation in Borrelia burgdorferi outer surface protein C, a critical virulence factor and potential Lyme disease vaccine candidate. Clin Vaccine Immunol 2011;18(6):901-6
   PubMed Web of Science ®Google Scholar
• Embers ME, Narasimhan S. Vaccination against Lyme disease: past, present, and future. Front Cell Infect Microbiol 2013;3
   Web of Science ®Google Scholar
• Fikrig E, Barthold SW, Kantor FS, Flavell RA. Protection of mice against the Lyme disease agent by immunizing with recombinant OspA. Science 1990;250(4980):553-6
   PubMed Web of Science ®Google Scholar
• Schaible UE, Kramer MD, Eichmann K, et al. Monoclonal antibodies specific for the outer surface protein A (OspA) of Borrelia burgdorferi prevent Lyme borreliosis in severe combined immunodeficiency (scid) mice. Proc Natl Acad Sci USA 1990;87(10):3768-72
   PubMed Web of Science ®Google Scholar
• Fikrig E, Barthold SW, Kantor FS, Flavell RA. Long-term protection of mice from Lyme disease by vaccination with OspA. Infect Immun 1992;60(3):773-7
   PubMed Web of Science ®Google Scholar
• Lovrich SD, Callister SM, DuChateau BK, et al. Abilities of OspA proteins from different seroprotective groups of Borrelia burgdorferi to protect hamsters from infection. Infect Immun 1995;63(6):2113-19
   PubMed Web of Science ®Google Scholar
• Chang YF, Appel MJ, Jacobson RH, et al. Recombinant OspA protects dogs against infection and disease caused by Borrelia burgdorferi. Infect Immun 1995;63(9):3543-9
   PubMed Web of Science ®Google Scholar
• de Silva AM, Telford SRIII, Brunet LR, et al. Borrelia burgdorferi OspA is an arthropod-specific transmission-blocking Lyme disease vaccine. J Exp Med 1996;183(1):271-5
   PubMed Web of Science ®Google Scholar
• Sikand VK, Halsey N, Krause PJ, et al. Safety and immunogenicity of a recombinant Borrelia burgdorferi outer surface protein A vaccine against lyme disease in healthy children and adolescents: a randomized controlled trial. Pediatrics 2001;108(1):123-8
   PubMed Web of Science ®Google Scholar
• Feder HM, Beran J, Van Hoecke C, et al. Immunogenicity of a recombinant Borrelia burgdorferi outer surface protein A vaccine against Lyme disease in children. J Pediatr 1999;135(5):575-9
   PubMed Web of Science ®Google Scholar
• Plotkin SA. Correcting a public health fiasco: The need for a new vaccine against Lyme disease. Clin Infect Dis 2011;52(Suppl 3):s271-5
   PubMed Web of Science ®Google Scholar
• Barrett PN, Portsmouth D. A novel multivalent OspA vaccine against Lyme borreliosis shows promise in Phase I/II studies 2013. Clin Vaccine Immunol 2014;21(11):1490-9
   PubMed Web of Science ®Google Scholar
• Gilmore RDJr, Kappel KJ, Dolan MC, et al. Outer surface protein C (OspC), but not P39, is a protective immunogen against a tick-transmitted Borrelia burgdorferi challenge: evidence for a conformational protective epitope in OspC. Infect Immun 1996;64(6):2234-9
   PubMed Web of Science ®Google Scholar
• Earnhart CG, Marconi RT. Construction and analysis of variants of a polyvalent Lyme disease vaccine: approaches for improving the immune response to chimeric vaccinogens. Vaccine 2007;25(17):3419-27
   PubMed Web of Science ®Google Scholar
• Schwan T. Temporal regulation of outer surface proteins of the Lyme-disease spirochaete Borrelia burgdorferi. Biochem Soc Trans 2003;31(1):108-12
   PubMed Web of Science ®Google Scholar
• Earnhart CG, Marconi RT. An octavalent lyme disease vaccine induces antibodies that recognize all incorporated OspC type-specific sequences. Hum Vaccin 2007;3(6):281-9
   PubMed Web of Science ®Google Scholar
• Earnhart CG, Buckles EL, Marconi RT. Development of an OspC-based tetravalent, recombinant, chimeric vaccinogen that elicits bactericidal antibody against diverse Lyme disease spirochete strains. Vaccine 2007;25(3):466-80
   PubMed Web of Science ®Google Scholar
• Eder G, Barrett N, Crowe B, et al. A candidate OspC Lyme disease vaccine under clinical investigation. Zentralblatt für Bakteriologie 1999;289(5):688-9
   Google Scholar
• Hanson M, Edelman R. Vaccines against Lyme disease. New Gener vaccines 2004;3:487-98
   Google Scholar
• Prybylski D. The cost-effectiveness of vaccinating against Lyme disease. Emerg Infect Dis 1999;5(5):727-8
   PubMed Web of Science ®Google Scholar